Banyu and Ono Begins Phase III Clinical Trials of a DPP-4 Inhibitor for Type 2 Diabetes Patients.Tokyo, Japan, Aug 7, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Banyu Pharmaceutical Co., Ltd. and Ono Pharmaceutical Co., Ltd. will begin Phase III Clinical Trial Noun 1. phase III clinical trial - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the of Sitagliptin (Development Code: MK-0431/ONO-5435) in Japan. Sitagliptin is a member of a potentially new class of oral drugs (DPP-4 inhibitors) that enhances the body's ability to lower blood sugar when it is elevated. In controlled international clinical development studies, sitagliptin demonstrated substantial reduction in blood sugar. The mechanism of DPP-4 inhibitors is distinct from that of any currently available class of glucose lowering agents. Banyu was in charge of phase II clinical trial Noun 1. phase II clinical trial - a clinical trial on more persons than in phase I; intended to evaluate the efficacy of a treatment for the condition it is intended to treat; possible side effects are monitored phase II and from phase III Noun 1. phase III - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the FDA onward, sitagliptin will be jointly developed by Banyu and Ono. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion